Rapid health technology assessment of anlotinib in treatment of advanced non-small cell lung cancer

Rapid health technology assessment of anlotinib in treatment of advanced non-small cell lung cancer

Objective To evaluate the efficacy, safety and cost-effectiveness of anlotinib in treatment of advanced non-small cell lung cancer (NSCLC) by rapid health technology assessment.Methods CNKI, Wanfang database, SinoMed, PubMed, The Cochrane Library and Embase were electronically searched to collect hi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shan SHEN, Jie YANG, Yun-Xia LIU, Hai-Ming MA, Ning HOU
Format:	Article
Language:	zho
Published:	Editorial Office of New Medicine 2021-10-01
Series:	Yixue xinzhi zazhi
Subjects:	anlotinib advanced non-small cell lung cancer rapid health technology assessment
Online Access:	https://yxxz.whuznhmedj.com/storage/attach/2110/DL8KBSV8GFyt18BAHPNlXjx4YnyZSNLIKy40xPH7.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study
by: Jin Xiong, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
by: Maojin You, et al.
Published: (2024-11-01)

A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
by: Hua-Jun Chen, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
by: Caicong You, et al.
Published: (2024-12-01)

Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
by: Hejing Bao, et al.
Published: (2024-11-01)

Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review
by: Xin Fei, et al.
Published: (2024-12-01)

Case report: Favorable efficacy of combined afatinib and anlotinib treatment in a lung adenocarcinoma patient harboring uncommon EGFR L858M/L861R mutations
by: Yueming He, et al.
Published: (2024-11-01)

Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study
by: Bolun Zhao, et al.
Published: (2024-08-01)

Dramatic response of advanced pulmonary sarcomatoid carcinoma to tislelizumab combined with anlotinib: a case report
by: Ranran Li, et al.
Published: (2025-02-01)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01)

Advances in biomarkers for immunotherapy in small-cell lung cancer
by: Hui Li, et al.
Published: (2024-12-01)

Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report
by: Haoyue Qin, et al.
Published: (2024-12-01)

Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
by: Yuanhang Wang, et al.
Published: (2024-12-01)

Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
by: Jiaxuan Liu, et al.
Published: (2025-01-01)

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
by: Zeyang Wang, et al.
Published: (2024-11-01)

Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review
by: Minghong Xie, et al.
Published: (2024-12-01)

Impact of donor lung bacteria detected by rapid on-site evaluation on early post-transplant outcomes in lung transplant recipients
by: Tianyang Liu, et al.
Published: (2025-01-01)

Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer
by: Han Li, et al.
Published: (2024-12-01)

The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)
by: Xueru Zhu, et al.
Published: (2025-12-01)

Surgery patterns and survival of T4N2 non-small cell lung cancer – A population-based analysis
by: Chenxi Zhang, et al.
Published: (2024-03-01)

Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer
by: Yong Zhang, et al.
Published: (2025-01-01)

Case report: Personalized management of treatment resistance in advanced NSCLC patients with mutated epidermal growth factor receptor: special examples and literature review
by: Jun Wang, et al.
Published: (2025-02-01)

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)

Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
by: Xiaowan Xie, et al.
Published: (2024-12-01)

Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer
by: Arnaud Colomb, et al.
Published: (2024-11-01)

Tocilizumab for Advanced Non‐Small‐Cell Lung Cancer With Concomitant Cachexia: An Observational Study
by: Yang Du, et al.
Published: (2024-12-01)

Results of the 2023 rapid DNA multi-laboratory study – RapidINTEL Plus sample cartridge
by: Erica L. Romsos, et al.
Published: (2024-12-01)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
by: Wentao Tian, et al.
Published: (2024-08-01)

Anti-inflammatory coupled anti-angiogenic airway stent effectively suppresses tracheal in-stents restenosis
by: Yanan Zhao, et al.
Published: (2025-01-01)

Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
by: Sarah Waliany, et al.
Published: (2024-12-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Transpulmonary chemoembolization and microwave ablation for recurrent or advanced non-small cell Lung Cancer
by: Thomas J. Vogl, et al.
Published: (2024-10-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

The effect of the relative dose intensity of chemoradiotherapy on the effectiveness of therapy of locally advanced unresectable non-small cell lung cancer
by: A. E. Glukhareva, et al.
Published: (2024-03-01)

Klinefelter syndrome diagnosed at autopsy and small-cell lung carcinoma
by: Haruyasu Sakuranaka, et al.
Published: (2025-01-01)

The importance of Ki-67 proliferation index in small cell lung cancer
by: Seda Beyhan Sağmen, et al.
Published: (2025-01-01)

LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival
by: Yunming Tao, et al.
Published: (2025-01-01)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
by: Margaux Geier, et al.
Published: (2020-10-01)

TREATMENT OF NON-SMALL CELL CARCINOMA OF LUNG IN SENILE PATIENTS
by: A. V. Reshetov, et al.
Published: (2015-08-01)

Development of brain metastases in non-small-cell lung cancer: high-risk features
by: Nolan Winslow, et al.
Published: (2024-12-01)